Sign In
Buy GIKLY
Grifols Sa Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | $0.0806 |
| EPS actual | $0.0866 |
| EPS Surprise | 7.35% |
| Revenue estimate | 2.031B |
| Revenue actual | 2.002B |
| Revenue Surprise | -1.45% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.148 |
| EPS actual | $0.145 |
| EPS Surprise | -2.36% |
| Revenue estimate | 2.345B |
| Revenue actual | 2.34B |
| Revenue Surprise | -0.202% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.121 |
| EPS actual | $0.109 |
| EPS Surprise | -9.52% |
| Revenue estimate | 2.153B |
| Revenue actual | 2.185B |
| Revenue Surprise | 1.49% |
| Release date | Aug 01, 2025 |
| EPS estimate | $0.113 |
| EPS actual | $0.100 |
| EPS Surprise | -11.26% |
| Revenue estimate | 1.857B |
| Revenue actual | 2.227B |
| Revenue Surprise | 19.88% |
Last 4 Quarters for Grifols Sa
Below you can see how GIKLY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 01, 2025 |
| Price on release | $7.45 |
| EPS estimate | $0.113 |
| EPS actual | $0.100 |
| EPS surprise | -11.26% |
| Date | Price |
|---|---|
| Jul 28, 2025 | $7.04 |
| Jul 29, 2025 | $7.04 |
| Jul 30, 2025 | $7.45 |
| Jul 31, 2025 | $7.49 |
| Aug 01, 2025 | $7.45 |
| Aug 04, 2025 | $7.49 |
| Aug 05, 2025 | $7.49 |
| Aug 06, 2025 | $7.49 |
| Aug 07, 2025 | $7.49 |
| 4 days before | 5.82% |
| 4 days after | 0.537% |
| On release day | 0.537% |
| Change in period | 6.39% |
| Release date | Nov 04, 2025 |
| Price on release | $6.85 |
| EPS estimate | $0.121 |
| EPS actual | $0.109 |
| EPS surprise | -9.52% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $6.85 |
| Oct 30, 2025 | $6.85 |
| Oct 31, 2025 | $6.70 |
| Nov 03, 2025 | $6.85 |
| Nov 04, 2025 | $6.85 |
| Nov 05, 2025 | $6.85 |
| Nov 06, 2025 | $6.85 |
| Nov 07, 2025 | $6.70 |
| Nov 10, 2025 | $6.01 |
| 4 days before | 0% |
| 4 days after | -12.23% |
| On release day | 0% |
| Change in period | -12.23% |
| Release date | Feb 26, 2026 |
| Price on release | $6.45 |
| EPS estimate | $0.148 |
| EPS actual | $0.145 |
| EPS surprise | -2.36% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $6.45 |
| Feb 23, 2026 | $6.45 |
| Feb 24, 2026 | $6.45 |
| Feb 25, 2026 | $6.45 |
| Feb 26, 2026 | $6.45 |
| Feb 27, 2026 | $6.45 |
| Mar 02, 2026 | $6.45 |
| Mar 03, 2026 | $6.45 |
| Mar 04, 2026 | $6.45 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | May 07, 2026 |
| Price on release | $5.30 |
| EPS estimate | $0.0806 |
| EPS actual | $0.0866 |
| EPS surprise | 7.35% |
| Date | Price |
|---|---|
| May 01, 2026 | $5.18 |
| May 04, 2026 | $5.18 |
| May 05, 2026 | $5.22 |
| May 06, 2026 | $5.22 |
| May 07, 2026 | $5.30 |
| May 08, 2026 | $5.30 |
| May 11, 2026 | $5.30 |
| May 12, 2026 | $5.30 |
| May 13, 2026 | $5.30 |
| 4 days before | 2.31% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 2.31% |
Grifols Sa Earnings Call Transcript Summary of Q1 2026
Grifols reported a Q1 2026 in-line quarter with reported revenue of €1.7bn (+3.3% cc) and adjusted EBITDA of €404m (€381m reported), driven by Biopharma which grew ~6.8% cc. Immunoglobulins (IG) were the primary growth engine (IG +15.3% cc), with strong momentum for Gamunex and Xembify and initial commercial contribution from Biotest's Yimmugo. Management reiterated 2026 targets: adjusted EBITDA margin goal of at least 25%, 5–9% adjusted EBITDA growth (cc), and full-year free cash flow improvement toward a €500–575m target. Strategic priorities highlighted: (1) a structural ramp of Egypt plasma collections (target ~1m liters in 2026, ~3m by 2029) to lower cost-per-liter and rebalance global sourcing; (2) optimization of U.S. plasma center footprint to improve CPL and margins; (3) continued integration and commercial rollout of Biotest assets (Yimmugo, fibrinogen products); (4) Diagnostics runway with the Barcelona next‑gen blood‑typing platform launching in Q2’26 and ISARD immunoassay plans after dissolution of the QuidelOrtho JV (Grifols to receive $65m compensation over 3 years); and (5) strict OpEx discipline. Financial position materially improved via proactive refinancing: net leverage ~4.3x, extended revolver (> $2bn) and pushed next major maturities to Q4’28, reducing near‑term refinancing risk. Key risks/near-term headwinds: albumin weakness in China (price/inventory effects) and Q1 seasonality/working‑capital build (Q1 free cash flow pre‑M&A was -€8m). Management also announced an initial process to evaluate a potential U.S. IPO of part of its U.S. Biopharma business (no further details disclosed).
